NASDAQ:RDHL RedHill Biopharma (RDHL) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free RDHL Stock Alerts $0.42 0.00 (-1.07%) (As of 12:36 PM ET) Add Compare Share Share Today's Range$0.40▼$0.4250-Day Range$0.38▼$0.6252-Week Range$0.26▼$3.28Volume249,450 shsAverage Volume1.09 million shsMarket Capitalization$12.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get RedHill Biopharma alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now. About RedHill Biopharma Stock (NASDAQ:RDHL)RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More RDHL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDHL Stock News HeadlinesApril 24, 2024 | finance.yahoo.comRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 StudyApril 18, 2024 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.comApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)April 10, 2024 | finance.yahoo.comRedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)April 9, 2024 | bizjournals.comRaleigh pharma weighs divesting commercial operationsApril 8, 2024 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsApril 8, 2024 | finance.yahoo.comRedHill Biopharma Ltd. (2RH0.F)April 8, 2024 | prnewswire.comRedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)April 2, 2024 | finance.yahoo.comRedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market PriceMarch 11, 2024 | markets.businessinsider.comRedHill Biopharma Receives New Patent For H. Pylori Treatment TaliciaMarch 11, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Covering Talicia® Through 2034March 5, 2024 | finance.yahoo.comRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsFebruary 20, 2024 | finance.yahoo.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 20, 2024 | prnewswire.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 16, 2024 | barrons.comRedHill Biopharma Ltd. ADRJanuary 26, 2024 | finance.yahoo.comRedHill Biopharma Announces Closing of $8 Million Registered Direct OfferingJanuary 25, 2024 | msn.comRedHill gains after new patent grant for Talicia for H. pylori treatment through 2042January 25, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042January 25, 2024 | finance.yahoo.comRedHill Biopharma Announces $8 Million Registered Direct OfferingJanuary 24, 2024 | benzinga.comWhy Redhill Biopharma Stock Is Moving HigherDecember 20, 2023 | msn.comRedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against EbolaDecember 20, 2023 | markets.businessinsider.comRedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus StudyDecember 20, 2023 | msn.comRedHill shares rally 20% on positive data for two antiviral drugsDecember 20, 2023 | finance.yahoo.comRedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against EbolaDecember 12, 2023 | msn.comRedHill Biopharma regains compliance with Nasdaq listing ruleDecember 4, 2023 | finance.yahoo.comRedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 StudySee More Headlines Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/30/2021Today4/25/2024Next Earnings (Estimated)6/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RDHL CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees113Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.61 Sales & Book Value Annual Sales$6.53 million Price / Sales1.91 Cash Flow$1.24 per share Price / Cash Flow0.34 Book Value$0.11 per share Price / Book3.82Miscellaneous Outstanding Shares29,700,000Free Float27,680,000Market Cap$12.47 million OptionableNo Data Beta3.45 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Dror Ben-Asher (Age 58)Co-Founder, Chairman & CEO Comp: $594.61kMr. Razi Ingber (Age 40)Chief Financial Officer Comp: $339.82kMr. Gilead Raday MPhil (Age 49)MSc, Chief Operating Officer Comp: $365.56kMr. Adi Frish (Age 54)Chief Corporate & Business Development Officer Comp: $339.3kMr. Rick D. Scruggs (Age 64)Chief Commercial Officer, President of RedHill Biopharma Inc. & Director Comp: $469.8kMs. Alexandra OkmianSenior Business Development & Investor Relations ManagerDr. Reza Fathi Ph.D. (Age 69)Senior Vice President of Research & Development Comp: $299.29kMr. Guy Goldberg J.D. (Age 48)Chief Business Officer Comp: $338.13kDr. June S. Almenoff FACP (Age 67)M.D., Ph.D., Chief Medical Officer Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsImunonNASDAQ:IMNNMIRA PharmaceuticalsNASDAQ:MIRAPurple BiotechNASDAQ:PPBTTonix PharmaceuticalsNASDAQ:TNXPAvalo TherapeuticsNASDAQ:AVTXView All Competitors RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed in 2024? RedHill Biopharma's stock was trading at $1.46 on January 1st, 2024. Since then, RDHL shares have decreased by 71.5% and is now trading at $0.4160. View the best growth stocks for 2024 here. When is RedHill Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024. View our RDHL earnings forecast. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) released its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to analysts' expectations of $23.41 million. During the same period in the prior year, the business earned ($20.00) earnings per share. When did RedHill Biopharma's stock split? Shares of RedHill Biopharma reverse split before market open on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA). How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RDHL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmith“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.